Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a mushroom extract boost lung cancer treatment?

NCT ID NCT07197853

Disease control Sponsor: Xin Ye Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding Huaier granules (a traditional Chinese medicine) to microwave ablation improves outcomes for people with stage IA non-small cell lung cancer who cannot have surgery. 180 participants will be randomly assigned to receive ablation alone or ablation plus Huaier granules for 72 weeks. The study will measure progression-free survival, tumor control, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Huaier granules (a traditional Chinese medicine extract) and microwave ablation
What this could lead to
If successful, this combination could offer a more effective treatment option for people with early-stage lung cancer who cannot have surgery, potentially improving tumor control and survival.
What could go wrong
This is a single-center trial, so results may not apply broadly. The addition of Huaier granules may not provide significant benefit over ablation alone, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Age: ≥ 18 years old. Diagnosis: Histologically or cytologically confirmed IA stage non-small cell lung cancer (NSCLC) that is inoperable. ECOG Performance Status: 0-2 (Eastern Cooperative Oncology Group performance status). Previous Treatment: Patients must have received no prior systemic treatment for lung cancer. Informed Consent: Ability to provide written informed consent and willingness to comply with study requirements. Adequate Organ Function: Patients must have adequate hepatic, renal, and hematologic function as evidenced by: Bilirubin ≤ 1.5 × upper limit of normal (ULN) ALT/AST ≤ 2.5 × ULN Creatinine clearance ≥ 30 mL/min Absolute neutrophil count (ANC) ≥ 1,500 cells/μL Exclusion Criteria Other Malignancies: Active or history of other malignancies within the past 5 years, except for non-melanoma skin cancer or in situ carcinoma. Severe Concurrent Diseases: Any serious or uncontrolled medical condition such as: Cardiovascular disease (e.g., recent myocardial infarction, unstable angina, or severe arrhythmia) Uncontrolled diabetes or hypertension Active infections requiring systemic antibiotics or antivirals Pregnancy or Breastfeeding: Women who are pregnant, breastfeeding, or planning to become pregnant during the study. Immunosuppressive Therapy: Patients who have received immunosuppressive therapy within 30 days prior to enrollment. Other Contraindications: Known hypersensitivity to any of the components of the treatment regimen (e.g., microwave ablation, Huai Er Granules). Other Unspecified Conditions: Any other condition or circumstances that, in the investigator's opinion, may interfere with the study or pose a risk to the patient. \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Huaier granules are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Huaier granules Microwave ablation Non-small cell lung cancer (NSCLC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.